Inhibikase Therapeutics, Inc. (NASDAQ:IKT – Get Free Report) has been assigned a consensus recommendation of “Buy” from the five brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a strong buy rating to the [...]
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Recommendation of “Buy” by Analysts
